Stroke prevention in atrial fibrillation: Past, present and future
|
|
- Richard Cummings
- 6 years ago
- Views:
Transcription
1 th Anniversary Stroke prevention in atrial fibrillation: Past, present and future Comparing the guidelines and practical decision-making Gregory Y. H. Lip 1,2,3 ; Ben Freedman 4,5 ; Raffaele De Caterina 6 ; Tatjana S. Potpara 3,7 1 Institute of Cardiovascular Science, University of Birmingham, Birmingham, UK; 2 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3 School of Medicine, Belgrade University, Belgrade, Serbia; 4 Heart Research Institute, Charles Perkins Centre, Sydney Medical School, University of Sydney, Sydney, Australia; 5 Department of Cardiology and Anzac Research Institute, Concord Hospital, University of Sydney, Australia; 6 G. d Annunzio University and Center of Excellence on Aging CeSI-Met, Chieti, Italy; 7 Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia Summary Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medicine will continue. In this review article, we provide an overview of past, present and the (likely) future concepts and approaches to stroke prevention in AF. We propose three simple steps (the Birmingham 3-step ) that offers a practical management pathway to help streamline and simplify decision-making for stroke prevention in patients with AF. Keywords Atrial fibrillation, stroke prevention, non-vitamin K antagonist oral anticoagulants, warfarin Correspondence to: Prof. G. Y. H. Lip University of Birmingham Institute of Cardiovascular Sciences City Hospital, Birmingham B18 7QH, United Kingdom Tel.: , Fax: g.y.h.lip@bham.ac.uk Received: November 22, 2016 Accepted after minor revision: January 2, 2017 Epub ahead of print: June 9, Thromb Haemost 2017; 117: Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief. Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF (1, 2). As the public health impact of AF increases, there also is an urgent need to simplify and streamline patient management pathways, with attention to improving patient adherence and persistence with stroke prevention therapies (3), as this will optimise outcomes and reduce the burden of stroke associated with AF (4). The past The historical randomised controlled trials (RCTs) comparing warfarin to placebo or control, conducted two decades ago, clearly showed that warfarin reduced stroke/systemic embolism by 64 % and all-cause mortality by 26 % (5, 6). Of note, these trials included less than 8000 patients in comparison with either nothing or antiplatelet agents mostly aspirin (5, 6). Clearly, warfarin (and the Vitamin K antagonists, VKA) became the standard of care when stroke prevention with OAC was needed. Nonetheless, the use of VKA was problematic, requiring regular anticoagulation monitoring to keep within a relatively narrow therapeutic range, and furthermore, VKAs were subject to much inter- and intra-patient variability, as well as diet and drug interactions (7). Furthermore, oral anticoagulation (OAC) with the VKAs was associated with increased bleeding risk, the most serious being intracranial bleeding (ICH). Hence, initial stroke prevention efforts were particularly directed towards identifying the high risk AF patients in whom stroke reduction benefits of OAC outweighed the bleeding risk. Clinical characteristics of patients in the non-vka treated or placebo arms of the historical RCTs were used to help identify clinical and echocardiographic risk factors for an increased risk of stroke, and the clinical features were used to formulate stroke risk stratification schemes, such as the CHADS 2 score (8). Whilst the latter was simple, it had only modest predictive value, as reflected by a c-index of approximately 0.60 (a statistical measure of the predictive value, where a c-index of 1.0 is perfect prediction, and 0.5 is 50:50 prediction) (9), similar to most risk scores based on clinical features. Thrombosis and Haemostasis 7/2017 Schattauer 2017
2 Lip et al. Stroke prevention in AF 1231 Attention was therefore directed towards echocardiographic parameters to refine stroke risk assessment, and the presence of moderate-severe left ventricular systolic impairment on two-dimensional echocardiography was independently predictive of stroke in AF (10). The availability of transoesphageal echocardiography allowed additional refinement, where the presence of spontaneous echo contrast, low left atrial appendage velocities and complex aortic plaque were independent predictors of thromboembolism (11), as was the presence of left atrial thrombus (12). The latter could be present asymptomatically in approximately 10 % of patients, even whilst on OAC (12). Nonetheless, the historical RCTs have been debated as they only randomised <10 % of patients screened, and many common risk factors associated with thromboembolism in AF were neither systematically recorded nor consistently defined. A systematic review by the Stroke in AF Working Group identified previous stroke (relative risk [RR] 2.5, 95 % confidence interval [CI] ), increasing age (RR 1.5 per decade, 95 %CI ) diabetes (1.7, ), and history of hypertension (2.0, ) as risk factors, whilst female sex was inconsistently associated with stroke but heart failure and coronary artery disease were inconclusive as risk factors (13). Other systematic reviews by the National institute for Health and Care Excellence (NICE) and Pisters et al. found evidence for structural heart disease (including prior myocardial infarction or cardiac dysfunction) and female sex as risk factors (14, 15). Nonetheless, additional information on stroke risk factors has been obtained from large observational cohorts. The present Stroke risk stratification and treatment decisions Currently, the CHA 2 DS 2 -VASc score (16) is commonly advocated in most guidelines (see Table 1), and extends the older CHADS 2 score by recognising additional risk factors. For example, age is a powerful driver of stroke risk, so that age gets one point, and age 75 gets 2 points; in Asian cohorts, where stroke risk seems higher than in non-asian cohorts, stroke risk seems to rise from age of 50 upwards, such that a recalibration of CHA 2 DS 2 -VASc has been proposed with 1 point for age 50 74, with a significant improvement in stroke prediction over the conventional CHA 2 DS 2 -VASc score (17). The V in CHA 2 DS 2 -VASc refers to complicated vascular disease, usually defined as myocardial infarction or revascularisation, peripheral artery disease or the presence of complex aortic plaque (18). The Sc (Sex category) criterion refers to female sex, which older literature suggested increased stroke risk (19), but it became apparent there was an agedependency to this risk, such that females aged <65 in the absence of any additional stroke risk factors were at low risk (with stroke rates of <1 %/year) (20). Also, the C criterion in CHA 2 DS 2 -VASc is broader than that in CHADS 2, and also refers to recent decompensated heart failure (usually indicated by a hospitalisation) irrespective of the left ventricular ejection fraction (LVEF) (21), thus including heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), cardiomyopathy, etc., as well as asymptomatic or symptomatic moderate-severe LV systolic impairment on cardiac imaging. Even a single stroke risk factor confers an accentuated risk of stroke and mortality, and the net clinical benefit (NCB) balancing stroke reduction against serious bleeding with OAC use is clearly positive in such patients, compared to aspirin or no treatment (22 24). In contrast, aspirin has a neutral or negative NCB, indicating no advantage even in patients with a CHA 2 DS 2 -VASc score of 1 (or 2 in females) (25). Whilst CHA 2 DS 2 -VASc includes the common stroke risk factors seen in everyday clinical practice, it does not include every possible stroke risk factor especially since some have less supportive evidence as an independent predictor. For example, AF patients with chronic kidney disease (CKD) are at high risk for stroke, death, myocardial infraction and bleeding but CKD does not appear to independently improve the predictive value of CHA 2 DS 2 -VASc, which is perhaps unsurprising since CKD is associated with the components of CHA 2 DS 2 -VASc such as age, heart failure, diabetes mellitus, vascular disease etc (26). As would be expected, the CHA 2 DS 2 -VASc score also predicts stroke and mortality in non-af populations, given it is essentially a cluster of the common risk factors for stroke and mortality (27, 28). The modest predictive value of CHA 2 DS 2 -VASc for identifying high risk patients can clearly be improved (at least statistically) by including substantially more clinical variables (QStroke, GAR- FIELD score), or the addition of biomarkers (29-31). With complicated clinical risk scores and multiple parameters, some refinement is possible, with a c-index statistically improved to approximately 0.7, especially with machine learning methodology of large cohorts. Biomarkers can clearly improve stroke prediction (32), and addition of any biomarker (whether blood, urine or imaging based) will always improve on clinical risk prediction, at least statistically and changing the c-index to This concept is not new, and even a decade ago (33), biomarkers were already shown to refine stroke risk stratification. The same biomarkers are also predictors of stroke, death, myocardial infarction and bleeding, and to weigh or balance these outcomes can only lead to treatment uncertainties and confusion in decision-making. Importantly, the predictive value of biomarkers should ideally be shown in nonanticoagulated general population cohorts, which is difficult, while recent studies proposing biomarkers have been conducted in highly selected anticoagulated RCT cohorts (31, 34). Also, complicated scores and multiple biomarkers and/or imaging simply add additional expense and reduce simplicity or practicality of widespread use in everyday clinical practice and busy clinics, especially since the default should be to offer stroke prevention (which is OAC) unless the patient is shown to be low risk. Moreover, most of the increase in risk prediction in these studies is by improving prediction in mid to high risk range, where all will require anticoagulation regardless of actual risk. The real clinical unmet need is to improve separation of the low risk subset who do not need anticoagulation from the intermediate risk group who would benefit, not provided by addition of current bio - Schattauer 2017 Thrombosis and Haemostasis 7/2017
3 1232 Lip et al. Stroke prevention in AF markers, and may be unethical to test prospectively in non-anticoagulated patients. The 2016 European Society of Cardiology (ESC) AF guidelines (35) use the CHA 2 DS 2 -VASc score in a categorised approach, Table 1: A comparison of the most recent ( ) guidelines published in English on antithrombotic prophylaxis in atrial fibrillation. Reference Scoring system recommended Recommendation for anticoagulation in general Recommendation for NOACs Recommendation for intermediaterisk patients Role of aspirin monotherapy JCS 2013 Circ J 2014; 78: (72) CHA 2 DS 2 Anticoagulation therapy based on risk assessment for cerebral infarction and bleeding is recommended. Class I LOE A NOACs should be considered, whenever indicated, as the first line therapy in patients with a CHADS 2 score of 2. Class I LOE A Anticoagulation therapy with rivaroxaban, edoxaban or warfarin should be considered for intermediate-risk patients with a CHA 2 DS 2 score of 1. LOE B Antiplatelet drugs may be considered for patients who cannot use oral anticoagulants. Class IIb LOE C NICE 2014 nice.org.uk/guidance/cg180 (73) CHA 2 DS 2 VASc For most people the benefit of anticoagulation outweighs the bleeding risk No specific preference for NOACs (apixaban, dabigatran etexilate, rivaroxaban) over warfarin in patients in whom anticoagulation is indicated Consider anticoagulation for men with a CHA 2 DS 2 VASc score of 1. Take the bleeding risk into account. Do not offer aspirin mono - therapy solely for stroke prevention to people with AF ACC/AHA 2014 J Am Coll Cardiol 2014; 64: e1 76 (36) CHA 2 DS 2 VASc With prior stroke, TIA, or CHA 2 DS 2 VASc score 2, Class I, LOE A Warfarin (Class I, LOE A) or a NOAC (dabigatran, rivaroxaban, or apixaban). Class I, LOE B With nonvalvular AF and a CHA 2 DS 2 VASc score of 1, no antithrombotic therapy or treatment with oral anticoagulant or aspirin may be considered. Class Iib LOE C With nonvalvular AF and a CHA 2 DS 2 VASc score of 1, no antithrombotic therapy or treatment with oral anticoagulant or aspirin may be considered. Class IIb LOE C where low risk is defined as a CHA 2 DS 2 -VASc score 0 (or 1 in females), moderate risk is a CHA 2 DS 2 -VASc score 1 in males (or 2 in females), and high risk is 2 stroke risk factors based on CHA 2 DS 2 -VASc; in these guidelines, high risk patients are recom- CCS 2016 Can J Cardiol 2016; 32: (74) CHADS-65 In general, oral anticoagulation (OAC) therapy is recommended for all patients with AF except those younger than 65 years of age with a Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/TIA (CHADS 2 ) score of 0. When OAC is indicated, a NOAC is recommended in preference to a VKA for nonvalvular AF (NVAF) (also with concomitant CAD) In CHADS 2 0 patients "aspirin (acetylsalicylic acid; ASA) is recommended in patients with CAD/vascular disease, and there is no indication for antithrombotic treatment in the absence of CAD/vascular disease". In CHADS 2 0 patients "aspirin (acetylsalicylic acid; ASA) is recommended in patients with CAD/vascular disease, and there is no indication for antithrombotic treatment in the absence of CAD/vascular disease". ESC 2016 Eur Heart J 2016; PMID: DOI: /eurheartj/ehw210 (35) CHA 2 DS 2 VASc Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA 2 DS 2 -VASc score of 2 or more. Class I LOE A Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA 2 DS 2 -VASc score of 3 or more. Class I LOE A When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist. Class I LOE A Oral anticoagulation therapy to prevent thromboembolism should be considered in male AF patients with a CHA 2 DS 2 VASc score of 1, considering individual characteristics and patient preferences. Class IIa LOE B Oral anticoagulation therapy to prevent hromboembolism should be considered in female AF patients with a CHA 2 DS 2 VASc score of 2, considering individual characteristics and patient preferences. Class IIa LOE B. Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk. Class III LOE B Thrombosis and Haemostasis 7/2017 Schattauer 2017
4 Lip et al. Stroke prevention in AF 1233 Table 1: Continued Combination therapy JCS 2013 A combination of antiplatelet and anticoagulant drugs may be considered for patients with CAD who undergo percutaneous coronary intervention (PCI) or surgical revascularisation. Iib LOE C NICE 2014 No specific recommendations given ACC/AHA 2014 After coronary re - vascularisation in patients with CHA 2 DS 2 VASc score 2, it may be reasonable to use clopidogrel concurrently with oral anticoagulants but without aspirin. Class IIb LOE B CCS 2016 It is recommended that patients who refuse warranted OAC therapy should receive the combination of ASA and clopidogrel. When CAD is present, some expert clinicians prefer a combination of a NOAC and ASA rather than a NOAC alone in preference to warfarin alone for patients perceived to be at higher risk of coronary events and low risk of major bleeding and might choose a NOAC alone as a reasonable option in those with average to lower risk of coronary events and higher risk of bleeding. ESC 2016 Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients without another indication for platelet inhibition. Class III LOE B Abbreviations: ACC/AHA = American College of Cardiology/American Heart Association; CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; ESC = European Society of Cardiology; JCS = Japanese Cardiovascular Society; LOE = Level of Evidence; NICE = National Institute for Health and Care Excellence (UK); NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; TIA = transient ischaemic attack. mended OAC (Class I recommendation), moderate risk patients should be considered for OAC (Class IIa recommendation) and low risk patients are recommended no antithrombotic therapy. The ESC guidelines do not recommend the use of aspirin solely for stroke prevention in AF. The 2014 AHA/ACC/ HRS (American Heart Association/American College of Cardiology/Heart Rhythm Society) guidelines (36) categorise risk as 0, 1 or 2 where those with score 0 are recommended no antithrombotic therapy, whilst those with score 2 are recommended OAC; however, those with score =1 are recommended nothing, aspirin or OAC depending on patient values and preferences and individualisation of therapy. Other guidelines are discussed further below. The continued mention of aspirin in guidelines may be one reason for its use as an option by some prescribers (37). To simplify and improve clinical management, we should perhaps start by avoiding the obsession with trying to identity a particular event rate for a particular point on the CHA 2 DS 2 -VASc score. Unsurprisingly, there would be a wide variation in reported event rates for particular scores points in different cohorts (38, 39), as stroke rates are dependent on study population, clinical setting, ethnicity, etc. Indeed, hospitalised cohorts have higher rates than community based AF population cohorts, but AF patients have high rates of hospitalisation whilst individual AF patients may be in the community and stable today, they may well be hospitalised next week, and even non-cardiovascular hospitalisations (e. g. from sepsis) increase the risk markedly. The electrophysiological characteristics of AF (AF pattern, atrial flutter, AF with a reversible cause, AF efficiently treated with drugs or ablation, brady-tachy syndrome, etc) are not relevant predictors for a higher or a lower risk of stroke, and are not sufficiently robust to decide on antithrombotic strategies. Also, with a single stroke risk factor, not all risk factors carry equal weight (40, 41). Of the CHA 2 DS 2 -VASc score factors, 1 point from age is a powerful driver of stroke risk but even within this category, the age of 65 is clearly lower risk than the age of 74 years. Also, well-controlled hypertension clearly has lower stoke risk compared to uncontrolled blood pressure, but what may be controlled hypertension today is not necessarily the case if patients do not take their antihypertensive medication. Notwithstanding the fact that even one stroke risk factor confers an excess risk of stroke and death, and that OAC has a positive NCB with one or more stroke risk factors (25), the CHA 2 DS 2 -VASc score should be used in a stepwise approach to initially identify low risk patients (Step 1), defined as a CHA 2 DS 2 -VASc score of 0 in males or 1 in females; such patients do not need any antithrombotic therapy. Step 2 is then to offer stroke prevention (i. e. OAC) to those with 1 stroke risk factors at this step it does not matter if the CHA 2 DS 2 -VASc score is 2, 3 or higher, or whether we have 1 or 10 biomarkers added, the patient merits stroke prevention to reduce the risk of a potentially fatal or severely disabling AF-related stroke. At Step 2, the decision with OAC these days is either a VKA with good quality anticoagulation control (as reflected by a good time in therapeutic range [TTR] >65 70 %), or a non-vka oral anticoagulant (NOAC), now tested against warfarin in over 80,000 patients. Despite the introduction of the NOACs, the VKAs are still widely used worldwide. However if VKAs are used, the challenge is how to identify those patients who are going to achieve a good TTR, as well as persistence with treatment, given that treatment discontinuations leads to more adverse outcomes (4). Many common clinical and genetic factors have been associated with labile INRs (42). The more common clinical factors have been used to formulate the SAMe-TT 2 R 2 score (43), which is a simple score that has been validated to identify those patients likely to do well on VKA with a good TTR (score 0 2) or those less likely to achieve a good TTR (score >2) that can be flagged up for more regular review with INR checks or education/counselling Schattauer 2017 Thrombosis and Haemostasis 7/2017
5 1234 Lip et al. Stroke prevention in AF (that has been shown to improve TTR) or these days, to be started on NOAC instead. The SAMe-TT 2 R 2 score has now been validated in multiple independent cohorts (44, 45), and not only helps to identify those patients less likely to do well on VKA but is predictive of labile INRs and the adverse outcomes associated with labile INRs, e. g. thromboembolism, death and bleeding. The SAMe- TT 2 R 2 score can therefore be incorporated into the patient pathway (Step 3). These three simple steps (the Birmingham 3-step ) offers a management pathway to help streamline decision-making for stroke prevention in patients with AF, and is illustrated in Figure 1. The NOACs have changed how we approach stroke prevention in AF, as they offer relative efficacy, safety and convenience compared to VKAs, in patients with AF, with an overall clear net clinical benefit (46, 47). The efficacy and safety of NOACs is even greater in Asians compared to non-asians. With specific antidotes or reversal agents already licensed and available for dabigatran (specifically, idarucizumab [48, 49]), or in development for the Factor Xa inhibitors (eg. andexanet alpha [50]), we are also in the era where we can essentially switch off any anticoagulation effect with the NOACs should the need arise, for example, following severe bleeding or the need for urgent surgery in a patient whilst on a NOAC (51, 52). The large Phase 3 NOAC clinical trials have been complemented by large post-marketing observational real world cohorts that augment and support the RCT data, showing effectiveness and safety with the NOACs versus warfarin these perhaps contrast the broad use of the new drugs in the real world against the artificial setting of a highly controlled protocol-based RCT cohort (53). The volume of these papers has largely reflected the sequence the individual NOACs were approved and marketed (54 57). Concerns about some adverse outcomes, such as myocardial infarction with some of the NOACs also seem unfounded (58). In the Danish registries, Larsen et al. (59) reported that all NOACs seemed to be safe and effective alternatives to warfarin in a routine care setting, and no significant differences were found between usual dose NOACs (dabigatran 150 mg bid, rivaroxaban 20 mg and apixaban 5 mg bid) and warfarin for ischaemic stroke. The risks of death, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran compared with warfarin. Comparative effectiveness or safety real world cohorts are also been published, and subtle differences are emerging and providing differentiation between the different NOAC agents (60). For example, the independent FDA Medicare analysis by Graham et al. (61) reported that treatment with rivaroxaban 20 mg once daily was associated with similar risks of thromboembolic stroke but statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily. Thus, apart from VKA (with good TTR), we have four NOACs licensed for AF stroke prevention compared to five years ago when prescribers did not have a choice (VKA only, nothing else), we are now spoilt for choice, and can fit the NOAC drug to particular patient characteristics (62, 63). After all, AF patients are not homogeneous, and to assume one drug fits all is simply unrealistic and misleading. Bleeding risk assessment The other side of the equation of thromboprophylaxis is bleeding risk assessment, which has been subject to many misconceptions and misuse (64). Unlike stroke risk factors, many bleeding risk factors can be modified and bleeding risk assessment is a dynamic process that needs evaluation at regular review and follow-up. Figure 1: The Birmingham 3-step. Management pathway to streamline decision-making for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis 7/2017 Schattauer 2017
6 Lip et al. Stroke prevention in AF 1235 Bleeding risk assessment is to flag up the patients potentially at high risk of bleeding for more careful follow-up and most importantly, to address the reversible bleeding risk factors. A high bleeding risk score is not an excuse to withhold OAC, as the NCB in such patients is often greater given that the stroke and bleeding risk track each other and the magnitude of gain from stroke reduction will far outweigh the small risk of serious bleeding. A history of falls is not a contraindication to OAC, and in a modelling analysis, the anticoagulated patient would need to fall 295 times per year, for the benefit of stroke reduction with OAC to be outweighed by the potential harm of serious bleeding (65). This is perhaps a simplification, as clearly a traumatic fall or uncontrolled epileptic seizures confers greater risk than less dangerous reasons for falls (e.g. syncope). Many bleeding risk factors have been identified, and the more common ones have been used to formulate bleeding risk scores, of which the HEMORR2HAGES, HAS-BLED, ATRIA, ORBIT and ABC-Bleeding scores have been derived for use in the AF population. The HAS-BLED score (66) has been popular, since it draws attention to the common reversible bleeding risk factors (uncontrolled blood pressure, labile INRs if on warfarin, excessive alcohol intake or concomitant use of aspirin or NSAIDs in an anticoagulated patient). The HAS-BLED has been validated in patients on no antithrombotic therapy, aspirin or anticoagulation (whether VKA or non-vka anticoagulants), and is therefore applicable at all stages in the patient management pathway. HAS-BLED has also been validated in AF and non-af populations, and is predictive of bleeding during bridging, acute coronary syndrome or percutaneous coronary interventions. Unlike other scores, HAS-BLED is also predictive of intracranial haemorrhage. Last, the simple HAS-BLED score performs as well as, and often superior, to other bleeding risk scores (67). Indeed, newer simple bleeding risk scores would significantly underperform in predicting bleeding whilst on VKA, as they do not consider labile INR or TTR as a criterion, and TTR is a powerful determinant of bleeding risks (67, 68). Figure 2: Thromboprophylaxis in AF a summary of the principal steps recommended by selected international guidelines. VKA: Vitamin K Antagonists; OAC: Oral Anticoagulant; CAD: Coronary Artery Disease; ASA: Acetyl Salicylic Acid; NOAC: Non-VKA Oral Anticoagulants; TTR: Time in Therapeutic Range; SAMe-TT 2 R 2 : female sex, age of <60 years, history of two or more co-morbidities (hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, and hepatic or renal disease) or treatment with drugs interacting with VKAs (e. g. amiodarone) 1 point each, tobacco use and non-caucasian ethnicity 2 points each. Schattauer 2017 Thrombosis and Haemostasis 7/2017
7 1236 Lip et al. Stroke prevention in AF Adherence, CVD risk management, and multi - disciplinary clinics One of the major issues with current anticoagulant treatment is that it is not always offered to patients at increased stroke risk according to guideline recommendation, often because of an overestimate of falls or bleeding risk, and an underestimate of risk from paroxysmal AF (69). Once prescribed, reduced adherence to anticoagulant therapy results in subtherapeutic levels, and discontinuation of anticoagulant: even after just one year following initiation, only about 65 % prescribed VKA, and 80 % for NOACs are still taking the drugs (4). Multidisciplinary nurse-led clinics have been proposed as a way to increase guideline and medication adherence, and improve outcomes, including addressing cardiovascular risk factors. The results appear favourable and cost effective (70, 71). What do the guidelines say? Table 1 summarises the principal international guidelines from the Japanese Cardiology Society (JCS) (72), National Institute for Health and Care Excellence (NICE) (73), AHA/ACC/ HRS (36), Canadian Cardiology Society (CCS) (74) and ESC (35). The principal decision steps have been summarised into Figure 2, where the Birmingham 3-step pathway is also shown to put decision making into context. While the ESC, AHA/ACC/HRS and NICE guidelines recommend the CHA 2 DS 2 -VASc score as the stroke assessment tool, the JCS guidelines opt for the use of CHADS 2 score with consideration of age 65 74, vascular disease and cardiomyopathy (i.e. other non- CHADS 2 components of the CHA 2 DS 2 -VASc score) and the CCS guidelines recommend a modified CHADS65 score ( Table 1). Both JCS and CCS well-acknowledge the role of additional stroke risk factors (i. e. age years, prior myocardial infarction, complex aortic plaque and peripheral arterial disease) which are included in the CHA 2 DS 2 -VASc score (excluding only female sex). As mentioned above, female sex-related risk of stroke is increased usually with the presence of 1 additional CHA 2 DS 2 -VASc stroke risk factors (thus, a female AF patient with no additional stroke risk factors would have a CHA 2 DS 2 -VASc score of 1 and should be classified into the truly low stroke risk stratum). The use of OAC in high-risk patients (that is, those with 2 stroke risk factors) and no therapy in AF patients without additional stroke risk factors is consistently recommended by all guidelines, whilst the recommendations for those at intermediate stroke risk (i.e. single stroke risk factor) are heterogeneous and include no therapy, aspirin or (preferably) OAC ( Table 1). When recommend OAC, the ESC, CCS and JCS guidelines give a preference to NOACs, whilst the NICE and AHA/ACC/HRS guidelines do not specify any preference to NOACs or VKAs. Also, the JCS guidelines specify that the target INR range with VKAs in patients aged 70 years should be (instead of in all other AF patients or in all other AF guidelines). Importantly, all guidelines make a distinction between so-called valvular versus non-valvular AF and recommend the use of NOAC only in patients with non-valvular AF, based on the results of the Phase 2 RE-ALIGN trial (75) which showed higher rates of stroke, valve thrombosis and major bleeding with dabigatran compared to warfarin. Valvular AF, which is currently not a satisfying terminology, has been defined in recent years as AF in patients with mechanical prosthetic heart valves or moderate-to severe mitral stenosis. All such patients should be given a VKA, whilst AF patients with any other heart valve abnormality may be given either NOACs or VKAs (76, 77). Stroke risk in such patients can also be assessed using the CHA 2 DS 2 -VASc score (78). All guidelines highlight the importance of bleeding risk management by addressing the modifiable bleeding risk factors and scheduling AF patients at increased risk of bleeding for a more intense clinical follow-up during OAC treatment. The NICE and JCS guidelines explicitly recommend the HAS-BLED score for bleeding risk assessment, whilst the AHA/ACC/HRS guidelines mention several bleeding risk scores without any formal recommendation, but with the notion that the HAS-BLED score better discriminates bleeding risk in comparison to the HEMORR2HAGES or ATRIA score. As discussed above, the ESC guidelines provide a long list of modifiable (uncontrolled hypertension, labile INR or TTR<60 % with VKAs, concomitant aspirin or non-steroidal antiinflammatory drug use, excessive alcohol use), potentially modifiable (anaemia, impaired renal or liver function, reduced platelet count or function) most of which are included in the HAS-BLED score and non-modifiable (age >65 years, previous bleeding, prior stroke, renal replacement therapy, liver cirrhosis, malignancy, genetic factors) or biomarker-based bleeding risk factors (e.g. high-sensitivity troponin). Whilst mentioning several bleeding risk scores (including the HAS-BLED, ORBIT and ABC scores), the ESC guidelines also do not provide any specific recommendation on the bleeding risk assessment tool or the definition of high-bleeding risk category, perhaps because a high-bleeding risk would not change the decision to initiate OAC, although this may be relevant with combination OAC and antiplatelet drugs in the setting of acute coronary syndrome or percutaneous coronary interventions. All guidelines provide guidance on the optimal management of special AF populations (e.g. elderly, patients with chronic kidney disease, etc.) or those presenting with an acute coronary syndrome, major bleeding or undergoing surgery or invasive procedures (79, 80). The ESC guidelines particularly extend on the management of acute stroke, major bleeding and the use of OAC post ICH, emphasising the role of integrated approach to AF management. Patient education and their values and preferences with respect to the management of stroke and bleeding risk are increasingly acknowledged in the formal AF guidelines. Finally, the ESC, AHA/ACC/HRS and NICE guidelines emphasise that documentation of AF using an electrocardiographic (ECG) or monitor/device recording is necessary for the diagnosis of AF, which is required before initiating stroke prevention therapy. Along with recommending opportunistic screening for AF by manual pulse checking (and subsequent ECG recording in those Thrombosis and Haemostasis 7/2017 Schattauer 2017
8 Lip et al. Stroke prevention in AF 1237 with palpated pulse irregularity) in all individuals aged >65 years (the ESC) or in individuals with symptoms suggestive of AF (the NICE), the ESC, NICE and AHA/ACC/HRS guidelines recommend prolonged screening for AF in post-stroke/tia patients, using short-term ECG recording followed by continuous ECGmonitoring for at least 72 hours. All three guidelines mention that long-term monitoring using non-invasive ECG monitors or implanted loop recorders should be considered for the detection of asymptomatic AF in post-stroke patients or to document AF in those with symptoms suggestive of paroxysmal AF. The ESC guidelines further emphasise the significance of detecting asymptomatic (or silent) AF by suggesting that systematic ECG screening may be considered in all individuals aged >75 years or at high risk of stroke (81), and added an ECG rhythm strip to pulse palpation as a recommended way to undertake opportunistic screening. The ESC guidelines also recommended regular device interrogation in patients implanted with pacemakers or implantable cardioverter defibrillators (ICD) for AF or atrial high rate episodes (AHRE). At present, the detection of AHRE should trigger further ECG monitoring to document AF before initiating stroke prevention therapy. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medicine will continue. As the NOACs are neither new nor novel anymore, new oral anticoagulants drugs targeting Factor IX, XI and other novel mechanisms are in development (90) as the quest for the holy grail of stroke prevention with no excess of bleeding continues. Conflicts of interest GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer-Ingelheim, Microlife and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. No fees are received personally. BF: Grants, personal fees, non-commercial support from Bayer; Personal fees from BMS/Pfizer, Boehringer-Ingelheim, Servier, AstraZeneca, Gilead (not in the area of atrial fibrillation or stroke). TSP: Consultant and speaker fees from Bayer, Pfizer, and Boehringer Ingelheim. RDC: Lecture fees and honoraria from Boehringer-Ingelheim, Bayer, BMS/Pfizer, Daiichi-Sankyo, Lilly, and Novartis; Research grants from Boehringer-Ingelheim, Bayer, BMS/Pfizer. The future The last 10 years has been an exciting time in the field of stroke prevention in AF, and in a modelling analysis, our data point to a substantial increase in the human and economic cost burden of AF and so emphasize the need to reduce this burden (82). This may be achieved by the increased use of OACs, particularly with the NOACs. Whilst we focus on stroke prevention in AF, many deaths in AF are actually not stroke related, and the majority are cardiovascular (83). OAC use is independently associated with a reduction in all cause, CV and non-cv mortality. Nonetheless, OAC use in patients with AF significantly reduces stroke to non-af rates, but whilst mortality is reduced, there is still an excess compared to non-af patients (84). Unanswered questions remain, for example, the use of OACs in AF patients with a prior ICH (85), significant valvular heart disease (78), the very elderly (86) and those with severe kidney disease (87), given that such patients were excluded from RCTs. Also, when to re-initiate OAC in high risk patients after a recent acute ischaemic stroke or gastrointestinal bleed (88, 89). In modelling the effect of the increasing use of NOACs in preference to warfarin in a European population with atrial fibrillation (AF), we recently estimated that the introduction of NOACs in 2010 eliminated over 88,000 thromboembolisms and deaths annually, of which over 17,000 were ischaemic strokes (82). At a oneyear cost of Euro 30k per ischaemic stroke, this strategy saved Euro 510 million annually. At a conservative rate of increase in the AF population of 2.2-fold from 2005, in 2050 there will be around 180,000 AF-related ischaemic strokes that, at an inflation-adjusted cost of around Euro 62k per stroke, sums to Euro 11,116 million. References 1. Kirchhof P, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: Freedman SB, Lowres N. Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. JAMA : the journal of the American Medical Association 2015; 314: Raparelli V, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2016; Martinez C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115: Hart RG, et al. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: Hart RG, et al. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: De Caterina R, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: Keogh C, et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe? Thromb Haemost 2010; 104: Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: Donal E, et al. EACVI/EHRA Expert Consensus Document on the role of multimodality imaging for the evaluation of patients with atrial fibrillation. Eur Heart joj Cardiovasc Imag 2016; 17: Di Minno MN, et al. Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. Thromb Haemost 2016; 115: Stroke Risk in Atrial Fibrillation Working G. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: Schattauer 2017 Thrombosis and Haemostasis 7/2017
9 1238 Lip et al. Stroke prevention in AF 14. Hughes M, et al. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: Pisters R, et al. Stroke and thromboembolism in atrial fibrillation. Circ J 2012; 76: Lip GY, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: Chao TF, et al. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Stroke 2016; 47: Violi F, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost 2016; 115: Wagstaff AJ, et al. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 2014; 107: Friberg L, et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. Br Med J 2012; 344: e Banerjee A, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012; 14: Fauchier L, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke 2016; 47: Hung Y, et al. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)? J Am Heart Assoc 2016; 5: pii: e Lip GY, Nielsen PB. Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke. Circulation 2016; 133: Lip GY, et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114: Friberg L, et al. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: Guo Y, et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 2016; 115: Melgaard L, et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischaemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. J Am Med Assoc 2015; 314: Hippisley-Cox J, et al. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. Br Med J 2013; 346: f Hijazi Z, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37: Ruff CT, et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. J Am Med Assoc Cardiol 2016; 1: Siegbahn A, et al. D-dimer and factor VIIa in atrial fibrillation prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost 2016; 115: Lip GY, et al. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: Hijazi Z, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387: Kirchhof P, et al ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; Epub ahead of print. 36. January CT, et al AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e Freedman SB, et al. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J 2015; 36: Quinn GR, et al. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients with Atrial Fibrillation. Circulation 2017; 135: Nielsen PB, Lip GYH. Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation. Circulation 2017; Epub ahead of print. 40. Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015; 113: Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc >/=1, or higher? Thromb Haemost 2015; 113: Wilson MR, et al. Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. Thromb Haemost 2016; 116: Apostolakis S, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT (2)R (2) score. Chest 2013; 144: Ruiz-Ortiz M, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: Bernaitis N, et al. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population. J Stroke Cerebrovasc Dis 2017; 26: Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: Renda G, et al. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. Am J Med 2015; 128: e Pollack CV, Jr., et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: Pollack CV, Jr., et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114: Connolly SJ, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: Greinacher A, et al. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: Ageno W, et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 2016; 116: Freedman B, Lip GY. Unreal world or real world data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost 2016; 116: Avgil-Tsadok M, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016; 115: Carmo J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116: Hecker J, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115: Beyer-Westendorf J, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: Darwiche W, et al. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb Haemost 2016; 116: Larsen TB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J 2016; 353: i Lip GY, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016; 116: Thrombosis and Haemostasis 7/2017 Schattauer 2017
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory DOI: 10.1016/j.cjca.2015.01.034
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationMEDLINE for studies published through March 11, 2015, that reported on AF and stroke, bleeding risk factors, and stroke prevention.
Clinical Review & Education Review A Systematic Review Gregory Y. H. Lip, MD; Deirdre A. Lane, PhD IMPORTANCE Atrial fibrillation (AF) is associated with an increase in mortality and morbidity, with a
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationStroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher?
Current Controversies 1165 Stroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher? Jonas Bjerring Olesen 1 ; Christian Torp-Pedersen 2 1 Department of Cardiology,
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
New Technologies, Diagnostic Tools and Drugs 981 Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationTechnology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249
Dabigatran an etexilate for the preventionention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249 NICE 2012. All
More informationControversies in Risk Stratification
Controversies in Risk Stratification There are more questions than answers So---Let me pose the questions Banff 2016 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationWhat are the risk factors for AF?
Susan Mayor was paid in her capacity as a medical writer for her time to research and write this article for Boehringer Ingelheim. This article has been reviewed by Boehringer Ingelheim to ensure compliance
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More information